Sheffield Diagnostic Genetics Service, Sheffield Children's NHS Foundation Trust and Haemostasis Research Group, Department of Cardiovascular Science, Sheffield, UK.
Haemophilia. 2012 Jul;18 Suppl 4:73-80. doi: 10.1111/j.1365-2516.2012.02832.x.
Congenital defects of platelets or plasma proteins involved in blood coagulation generally lead to bleeding disorders. In some of these disorders, patients with a severe phenotype are prone to spontaneous bleeds with critical consequences. This situation occurs more commonly in haemophilia A and haemophilia B and to a certain extent in severe forms (type 3) of von Willebrand disease. Defects in other plasma coagulation proteins and platelet factors are relatively rare, with an incidence of ≤ 1: 1-2 million. Molecular genetic studies of the human coagulation factors, especially factors VIII and IX, have contributed to a better understanding of the biology of these genetic disorders, the accurate detection of carriers and genetic counselling, and have also fostered new therapeutic strategies. This article reviews the evolution of genetics over the last five decades as a tool for bleeding disorder investigations, the recent advances in molecular techniques that have contributed to improved genetic diagnosis of this condition, and the development and utility of proficiency testing programmes and reference materials for genetic diagnosis of bleeding disorders.
先天性血小板或血浆蛋白缺陷,这些缺陷通常会导致凝血功能障碍。在这些疾病中,一些具有严重表型的患者容易发生自发性出血,且可能会产生严重后果。这种情况在血友病 A 和血友病 B 中更为常见,在一定程度上在严重形式(3 型)的血管性血友病中也较为常见。其他血浆凝血蛋白和血小板因子的缺陷相对较少,发病率为≤1:1-200 万。对人类凝血因子,特别是因子 VIII 和 IX 的分子遗传学研究,有助于更好地了解这些遗传疾病的生物学特性、携带者的准确检测和遗传咨询,也促进了新的治疗策略的发展。本文综述了过去五十年中遗传学作为出血性疾病研究工具的发展,以及分子技术的最新进展,这些进展有助于改善该疾病的遗传诊断,以及出血性疾病遗传诊断的能力验证计划和参考材料的开发和应用。